10x Genomics, Inc. 10-Q

Financial Statements (unaudited)

Item 1. Financial Statements. 10x Genomics, Inc. Condensed Consolidated Balance Sheets (In thousands) June 30, 2026 December 31, 2025 (Unaudited) (Note 1) Assets Current assets: Cash and cash equivalents $ 502,512 $ 473,966 Marketable securities 49,521 49,443 Accounts receivable, net 47,545 47,013 Other receivables 3,084 35,480 Inventory 52,616 56,341 Prepaid expenses and other current assets 19,393 22,208 Total current assets 674,671 684,451 Property and equipment, net 215,324 226,711 Operating lease right-of-use assets 56,685 60,450 Goodwill 6,918 4,511 Intangible assets, net 61,160 62,329 Other noncurrent assets 15,308 2,913 Total assets $ 1,030,066 $ 1,041,365 Liabilities and stockholders’ equity Current liabilities: Accounts payable $ 20,694 $ 12,733 Accrued compensation and related benefits 24,744 42,500 Accrued expenses and other current liabilities 30,377 39,971 Deferred revenue 23,610 23,902 Operating lease liabilities 12,015 10,985 Contingent consideration, current 7,069 23,363 Total current liabilities 118,509 153,454 Contingent consideration, noncurrent 2,991 1,237 Operating lease liabilities, noncurrent 66,781 73,376 Deferred revenue, noncurrent 9,683 10,501 Other noncurrent liabilities 6,556 6,471 Total liabilities 204,520 245,039 Commitments and contingencies (Note 5) Stockholders’ equity: Preferred stock — — Common stock 2 2 Additional paid-in capital 2,367,459 2,306,690 Accumulated deficit ( 1,541,992 ) ( 1,510,591 ) Accumulated other comprehensive income 77 225 Total stockholders’ equity 825,546 796,326 Total liabilities and stockholders’ equity $ 1,030,066 $ 1,041,365 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 2 Table of Contents 10x Genomics, Inc. Condensed Consolidated Statements of Operations (Unaudited) (In thousands, except share and per share data) Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Products and services revenue $ 149,094 $ 145,157 $ 298,990 $ 282,980 License and royalty revenue 1,942 27,751 2,889 44,811 Revenue 151,036 172,908 301,879 327,791 Cost of products and services revenue 38,539 47,824 83,204 97,262 Gross profit 112,497 125,084 218,675 230,529 Operating expenses: Research and development 56,791 61,224 113,638 125,469 Selling, general and administrative 78,661 74,434 145,038 164,162 Gain on settlement ( 3,400 ) ( 40,700 ) (